Edition:
United States

Argos Therapeutics Inc (ARGS.OQ)

ARGS.OQ on NASDAQ Stock Exchange Global Market

0.38USD
4:00pm EDT
Change (% chg)

$-0.01 (-2.33%)
Prev Close
$0.39
Open
$0.41
Day's High
$0.41
Day's Low
$0.37
Volume
125,034
Avg. Vol
189,104
52-wk High
$7.04
52-wk Low
$0.31

ARGS.OQ

Chart for ARGS.OQ

About

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $16.13
Shares Outstanding(Mil.): 41.35
Dividend: --
Yield (%): --

Financials

  ARGS.OQ Industry Sector
P/E (TTM): -- 14.09 19.01
EPS (TTM): -1.89 -- --
ROI: -313.99 -6.73 -5.03
ROE: -- -6.18 -4.28

BRIEF-Argos Therapeutics announces $6 mln secured convertible note financing

* Argos Therapeutics announces $6,000,000 secured convertible note financing

Jun 16 2017

BRIEF-Argos therapeutics provides update on ADAPT trial following meeting with FDA

* Argos provides update on its ADAPT trial following meeting with FDA

May 10 2017

BRIEF-Argos Reports interim results of the ADAPT trial

* Argos reports interim results of the ADAPT trial and provides perspective on decision to continue the trial

Apr 18 2017

BRIEF-Argos Therapeutics board approves plan to streamline operations

* Argos Therapeutics Inc - on March 8, 2017, board approved a workforce action plan designed to streamline operations and reduce company's operating expenses

Mar 09 2017

BRIEF-Argos says independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T

* Independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T in metastatic renal cell carcinoma for futility following its planned interim data review

Feb 22 2017

BRIEF-Argos Therapeutics files for mixed shelf of up to $200 mln

* Files for mixed shelf of up to $200 million - sec filing Source (http://bit.ly/2jbwENR) Further company coverage:

Jan 09 2017

More From Around the Web

Earnings vs. Estimates